Novo Nordisk A/S (NOV.F)
- Previous Close
117.40 - Open
117.70 - Bid 117.70 x --
- Ask --
- Day's Range
116.82 - 119.46 - 52 Week Range
67.85 - 127.90 - Volume
2,350 - Avg. Volume
7,797 - Market Cap (intraday)
530.332B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
47.31 - EPS (TTM)
2.50 - Earnings Date --
- Forward Dividend & Yield 1.72 (1.45%)
- Ex-Dividend Date Mar 22, 2024
- 1y Target Est
--
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.comRecent News: NOV.F
Performance Overview: NOV.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NOV.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NOV.F
Valuation Measures
Market Cap
530.34B
Enterprise Value
529.90B
Trailing P/E
47.38
Forward P/E
38.31
PEG Ratio (5yr expected)
2.44
Price/Sales (ttm)
17.07
Price/Book (mrq)
36.93
Enterprise Value/Revenue
2.28
Enterprise Value/EBITDA
4.62
Financial Highlights
Profitability and Income Statement
Profit Margin
36.03%
Return on Assets (ttm)
23.39%
Return on Equity (ttm)
88.07%
Revenue (ttm)
232.26B
Net Income Avi to Common (ttm)
83.68B
Diluted EPS (ttm)
2.50
Balance Sheet and Cash Flow
Total Cash (mrq)
30.23B
Total Debt/Equity (mrq)
25.34%
Levered Free Cash Flow (ttm)
54.1B
Company Insights: NOV.F
NOV.F does not have Company Insights